What makes Kadimastem unique in its approach to cell therapy?

​

“Most cell-based therapies are likely to be autologous, where stem cells are harvested from a specific tissue of a patient and cultured to create large quantities over many weeks and then returned to the same patient.

Moreover, the cells had been taken from a patient that had already manifested the disease. Another major hurdle of an autologous solution is the need for a lengthy procedure for each patient and the inability to create a ready-to-use product.

We are focused on our two main cell therapy products we invest all our efforts to bringing “off-the-shelf” products to the clinic in the best quality. We accumulated significant knowledge on cell growth, scalability, freezing methodologies, cell characterization, and we are open to new collaborations that can help improve and progress the regenerative medicine field.

One key issue is getting them from the bench to the bedside without compromising safety and efficacy. The successful commercialization of cellular therapeutics requires extending the shelf-life of these therapies through a developmental process called cryopreserved. We are moving fast with this process with AstroRx® and IsletRx. This development will allow banking of large quantities of cell products for broader distribution supporting the next advanced clinical trials and marketing phase.”
Dr. Michal Izrael, PhD